Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.

Molecular cancer therapeutics - 1 Apr 2017

Packer Leisl M, Geng Xinyan, Bonazzi Vanessa F, Ju Robert J, Mahon Clare E, Cummings Margaret C, Stephenson Sally-Anne, Pollock Pamela M

Abstract excerpt

Improved therapeutic approaches are needed for the treatment of recurrent and metastatic endometrial cancer. Endometrial cancers display hyperactivation of the MAPK and PI3K pathways, the result of somatic aberrations in genes such as FGFR2, KRAS, PTEN, PIK3CA, and PIK3R1 The FGFR2 and PI3K pathways, have emerged as potential therapeutic targets in endometrial cancer. Activation of the PI3K pathway is seen in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Morpholines

Share to Phenylurea Compounds

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Thiazoles

Source

Identifiers

PMID: 28119489
DOI: 10.1158/1535-7163.MCT-16-0415

Genes

FGFR2
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.PMID 28119489Read ↗

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.Semantic proximity Read ↗

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.Semantic proximity Read ↗

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.Semantic proximity Read ↗

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.Semantic proximity Read ↗

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.Semantic proximity Read ↗

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.Semantic proximity Read ↗

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.Semantic proximity Read ↗

PI3K pathway in gynecologic malignancies.Semantic proximity Read ↗

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.Semantic proximity Read ↗

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.Semantic proximity Read ↗

FGFR2 as a molecular target in endometrial cancer.Semantic proximity Read ↗

Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.